The use of rituximab therapy in patients with acquired factor V inhibitors.
Department of Hematology, Alvarez General Hospital, Buenos Aires, Argentina. m.a.navarrete@lumc.nl
M A
MA
Navarrete
F J M
FJ
van der Meer
G
G
Damiani
A
A
Diaz
J
J
Eikenboom
D000368:Aged; D000818:Animals; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D002417:Cattle; D005165:Factor V; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy*; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000069283:Rituximab; D013917:Thrombin / Q000008:administration & dosage / Q000009:adverse effects
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D019774:Blood Coagulation Factor Inhibitors; D006490:Hemostatics; D000069283:Rituximab; D005165:Factor V; D013917:Thrombin